# OnCo record dmmr-ihc (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/dmmr-ihc/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "dmmr-ihc" ;
  schema:name "dMMR (mismatch repair deficiency by IHC)"@en ;
  schema:alternateName "dMMR"@en, "MMR-deficient"@en, "mismatch repair deficient"@en, "MMRd"@en, "loss of MLH1"@en, "loss of MSH2"@en, "loss of MSH6"@en, "loss of PMS2"@en, "MMR IHC"@en, "MMR protein loss"@en ;
  schema:description "dMMR means one of the four mismatch repair proteins is missing from the tumour cell nuclei on a stain. It is the tissue-level twin of MSI-high and opens checkpoint immunotherapy in endometrial, bowel and many other cancers."@en ;
  schema:url <https://onco.cc/biomarkers/dmmr-ihc/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=095eab9f-545a-4f12-bfb7-19477fb901a5> ;
  onco:tag "biomarker", "mmr" ;
  onco:related <https://onco.cc/biomarkers/msi-high/>, <https://onco.cc/biomarkers/tmb-high/> ;
  onco:cancers <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/endometrial-mmr-deficient/>, <https://onco.cc/cancers/colorectal/>, <https://onco.cc/cancers/gastric-msi-high/>, <https://onco.cc/cancers/metastatic-cancer/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/msi-high-pdac/>, <https://onco.cc/cancers/gallbladder/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/prostate/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/dostarlimab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/ipilimumab/>, <https://onco.cc/drugs/durvalumab/>, <https://onco.cc/drugs/ventana-mmr-rxdx/> ;
  onco:terms <https://onco.cc/terms/msi/>, <https://onco.cc/terms/mlh1-promoter-methylation/>, <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/tumour-agnostic/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-ren-tnbc-mmr-msi-440-front-oncol-2021/>, <https://onco.cc/key-papers/paper-hu-mismatch-repair-deficiency-pancreatic-adenocarcinoma-ccr-2018/>, <https://onco.cc/key-papers/paper-luchini-msi-dmmr-pancreatic-systematic-review-gut-2021/>, <https://onco.cc/key-papers/paper-moreira-lynch-syndrome-identification-jama-2012/>, <https://onco.cc/key-papers/paper-herman-mlh1-promoter-hypermethylation-colorectal-pnas-1998/>, <https://onco.cc/key-papers/paper-weisenberger-cimp-braf-mlh1-colorectal-nat-genet-2006/>, <https://onco.cc/key-papers/paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017/>, <https://onco.cc/key-papers/paper-goeppert-cholangiocarcinoma-mmr-deficiency-bjc-2019/>, <https://onco.cc/key-papers/paper-wardell-biliary-drivers-germline-j-hepatol-2018/>, <https://onco.cc/key-papers/paper-guedes-msh2-loss-primary-prostate-ccr-2017/>, <https://onco.cc/key-papers/paper-abida-msi-prostate-checkpoint-blockade-jama-oncol-2019/> .